JP2002131322A - 乳管からの物質の同定 - Google Patents

乳管からの物質の同定

Info

Publication number
JP2002131322A
JP2002131322A JP2001226849A JP2001226849A JP2002131322A JP 2002131322 A JP2002131322 A JP 2002131322A JP 2001226849 A JP2001226849 A JP 2001226849A JP 2001226849 A JP2001226849 A JP 2001226849A JP 2002131322 A JP2002131322 A JP 2002131322A
Authority
JP
Japan
Prior art keywords
breast
protein
duct
marker
ductal fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001226849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002131322A5 (https=
Inventor
David Hung
デイビッド ハン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pro Duct Health Inc
Original Assignee
Pro Duct Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Duct Health Inc filed Critical Pro Duct Health Inc
Publication of JP2002131322A publication Critical patent/JP2002131322A/ja
Publication of JP2002131322A5 publication Critical patent/JP2002131322A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M3/00Medical syringes, e.g. enemata; Irrigators
    • A61M3/02Enemata; Irrigators
    • A61M3/0233Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs
    • A61M3/0254Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs the liquid being pumped
    • A61M3/0262Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs the liquid being pumped manually, e.g. by squeezing a bulb
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M3/00Medical syringes, e.g. enemata; Irrigators
    • A61M3/02Enemata; Irrigators
    • A61M3/0279Cannula; Nozzles; Tips; their connection means
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0041Detection of breast cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00Anatomical parts of the body
    • A61M2210/10Trunk
    • A61M2210/1007Breast; mammary

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
JP2001226849A 2000-07-26 2001-07-26 乳管からの物質の同定 Withdrawn JP2002131322A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/625,399 US6610484B1 (en) 1999-01-26 2000-07-26 Identifying material from a breast duct
US09/625,399 2000-07-26

Publications (2)

Publication Number Publication Date
JP2002131322A true JP2002131322A (ja) 2002-05-09
JP2002131322A5 JP2002131322A5 (https=) 2008-09-11

Family

ID=24505894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001226849A Withdrawn JP2002131322A (ja) 2000-07-26 2001-07-26 乳管からの物質の同定

Country Status (6)

Country Link
US (4) US6610484B1 (https=)
EP (1) EP1182459A3 (https=)
JP (1) JP2002131322A (https=)
AU (1) AU762211B2 (https=)
CA (1) CA2353193A1 (https=)
IL (1) IL144514A0 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532082A (ja) * 2001-05-30 2004-10-21 ネオマトリックス・エルエルシー 非侵襲性管内流体診断スクリーン
JP2009515166A (ja) * 2005-11-02 2009-04-09 バイエル ヘルスケア エルエルシー がんの予測及び予後の検査方法、並びにがん治療のモニタリング
JP2009515167A (ja) * 2005-11-02 2009-04-09 バイエル ヘルスケア エルエルシー がんの予測及び予後の検査方法、並びにがん治療のモニタリング
JP2009219932A (ja) * 2001-05-30 2009-10-01 Neomatrix Llc 管内流体吸入装置用ディスポーザブル患者インターフェース
JP2012501440A (ja) * 2008-09-01 2012-01-19 アトラス・アンティボディーズ・アクチボラゲット 内分泌処置予測因子としてのanlnタンパク質
WO2014038524A1 (ja) 2012-09-05 2014-03-13 和光純薬工業株式会社 乳癌の判定方法
WO2014132869A1 (ja) 2013-02-26 2014-09-04 和光純薬工業株式会社 乳癌の判定法
KR20220034725A (ko) * 2019-05-02 2022-03-18 더 호스피탈 포 식 칠드런 브루가다 증후군과 관련된 바이오마커의 검출

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020110609A1 (en) * 1998-12-28 2002-08-15 David Hung Increasing retrievable fluid from a breast duct
US6413228B1 (en) * 1998-12-28 2002-07-02 Pro Duct Health, Inc. Devices, methods and systems for collecting material from a breast duct
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
CA2370539C (en) 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
US6642009B2 (en) 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
US20040153001A1 (en) * 1999-12-28 2004-08-05 David Hung Devices, methods and systems for collecting material from a breast duct
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2002031507A2 (en) * 2000-10-13 2002-04-18 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
US20040137539A1 (en) * 2003-01-10 2004-07-15 Bradford Sherry A. Cancer comprehensive method for identifying cancer protein patterns and determination of cancer treatment strategies
US7666583B2 (en) 2004-02-19 2010-02-23 Yale University Identification of cancer protein biomarkers using proteomic techniques
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060057638A1 (en) * 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20070243540A1 (en) * 2004-05-21 2007-10-18 Tsai Jo C Kits and Methods for Identification, Assessment, Prevention and Therapy of Breast Cancer
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
CN101379400A (zh) * 2005-12-22 2009-03-04 诺华有限公司 可溶性人m-csf受体及其应用
WO2007098102A2 (en) * 2006-02-17 2007-08-30 Children's Medical Center Corporation Free ngal as a biomarker for cancer
EP3796002B1 (en) * 2006-07-14 2023-11-22 The Regents of The University of California Cancer biomarkers and methods of use thereof
KR20090071603A (ko) * 2006-09-19 2009-07-01 노파르티스 아게 Raf 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2010041423A1 (ja) * 2008-10-09 2010-04-15 日本電気株式会社 病理組織診断支援システム、病理組織診断支援プログラム、病理組織診断支援方法
US20100136579A1 (en) * 2008-12-02 2010-06-03 Industrial Technology Research Institute Biomarkers useful in liver fibrosis diagnosis
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
JP5387146B2 (ja) * 2009-06-03 2014-01-15 日本電気株式会社 病理組織画像解析装置、病理組織画像解析方法、病理組織画像解析プログラム
WO2011031517A1 (en) 2009-08-27 2011-03-17 Nuclea Biotechnologies, LLC Method and assay for determining fas expression
WO2011139721A1 (en) 2010-04-27 2011-11-10 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
WO2016090323A1 (en) 2014-12-05 2016-06-09 Prelude, Inc. Dcis recurrence and invasive breast cancer
US10151001B2 (en) 2014-12-29 2018-12-11 National Guard Health Affairs Quantification of Lamin C and Lamin A for tumor classification
EP3414394B1 (en) * 2016-02-08 2023-09-13 GPCP IP Holdings LLC Molding roll for making paper products
WO2020056338A1 (en) 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
CN111521312A (zh) * 2020-05-08 2020-08-11 中国工程物理研究院化工材料研究所 一种基于盲孔法标定光纤测量材料残余应力的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4782015A (en) 1984-03-30 1988-11-01 Syntex (U.S.A.) Inc. Method for determining the presence of malignant cells
EP0319686A3 (en) 1987-10-21 1991-04-24 Mochida Pharmaceutical Co., Ltd. Method for assaying a target substance in a minute amount of nipple discharge and device for such an assay
EP0636248A4 (en) 1992-04-14 1996-11-13 Univ Duke METHOD FOR DETECTING P53 AND HSP70 COMPLEX CONTAINING TUMORS.
US5478556A (en) 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
WO1997005898A1 (en) 1995-08-03 1997-02-20 The Johns Hopkins University School Of Medicine Delivery of an agent to the ductal epithelium in the prophylactic and therapeutic treatment of cancer
US5763415A (en) 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
US5914238A (en) 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
US5798266A (en) 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US6168779B1 (en) * 1997-09-16 2001-01-02 The Regents Of The University Of California Methods and kits for identifying ductal orifices
US6221622B1 (en) * 1998-04-28 2001-04-24 The Regents Of The University Of California Method and kit for obtaining fluids and cellular material from breast ducts
US6046929A (en) * 1998-04-06 2000-04-04 Fujitsu Limited Memory device with two ferroelectric capacitors per one cell
US6287790B1 (en) * 1998-11-30 2001-09-11 The Regents Of The University Of California Utilization of nuclear structural proteins for targeted therapy and detection of proliferative and differentiation disorders
DE60035499T2 (de) 1999-05-17 2008-03-20 Cytyc Corp., Marlborough Identifizierung von material aus dem milchkanal der brust
JP4667594B2 (ja) * 2000-12-25 2011-04-13 ルネサスエレクトロニクス株式会社 薄膜磁性体記憶装置

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532082A (ja) * 2001-05-30 2004-10-21 ネオマトリックス・エルエルシー 非侵襲性管内流体診断スクリーン
JP2009219932A (ja) * 2001-05-30 2009-10-01 Neomatrix Llc 管内流体吸入装置用ディスポーザブル患者インターフェース
JP2009515166A (ja) * 2005-11-02 2009-04-09 バイエル ヘルスケア エルエルシー がんの予測及び予後の検査方法、並びにがん治療のモニタリング
JP2009515167A (ja) * 2005-11-02 2009-04-09 バイエル ヘルスケア エルエルシー がんの予測及び予後の検査方法、並びにがん治療のモニタリング
JP2012501440A (ja) * 2008-09-01 2012-01-19 アトラス・アンティボディーズ・アクチボラゲット 内分泌処置予測因子としてのanlnタンパク質
WO2014038524A1 (ja) 2012-09-05 2014-03-13 和光純薬工業株式会社 乳癌の判定方法
JPWO2014038524A1 (ja) * 2012-09-05 2016-08-08 和光純薬工業株式会社 乳癌の判定方法
WO2014132869A1 (ja) 2013-02-26 2014-09-04 和光純薬工業株式会社 乳癌の判定法
KR20220034725A (ko) * 2019-05-02 2022-03-18 더 호스피탈 포 식 칠드런 브루가다 증후군과 관련된 바이오마커의 검출
JP2022531508A (ja) * 2019-05-02 2022-07-06 ザ ホスピタル フォー シック チルドレン ブルガダ症候群関連バイオマーカーの検出
JP7547470B2 (ja) 2019-05-02 2024-09-09 ザ ホスピタル フォー シック チルドレン ブルガダ症候群関連バイオマーカーの検出
KR102826926B1 (ko) 2019-05-02 2025-06-27 더 호스피탈 포 식 칠드런 브루가다 증후군과 관련된 바이오마커의 검출

Also Published As

Publication number Publication date
US20120034644A1 (en) 2012-02-09
EP1182459A2 (en) 2002-02-27
IL144514A0 (en) 2002-05-23
EP1182459A3 (en) 2003-01-08
US20130078650A1 (en) 2013-03-28
CA2353193A1 (en) 2002-01-26
US20040018546A1 (en) 2004-01-29
AU5767901A (en) 2002-01-31
US6610484B1 (en) 2003-08-26
AU762211B2 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
JP2002131322A (ja) 乳管からの物質の同定
US6642009B2 (en) Isolated ductal fluid sample
US6638727B1 (en) Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
Bellizzi et al. Pancreatic cytopathology: a practical approach and review
AU2002237838A1 (en) Isolated ductal fluid sample
US6673024B2 (en) Cytological evaluation of breast duct epithelial cells retrieved by ductal lavage
ES2288480T3 (es) Identificacion de material procedente de un conducto mamario.
AU2001277214A2 (en) Cytological evaluation of breast duct epithelial cells retrieved by ductal lavage
AU2001277214A1 (en) Cytological evaluation of breast duct epithelial cells retrieved by ductal lavage
JP2003529318A (ja) 乳管から材料を採取するための装置、方法、およびシステム
IL146374A (en) Method for identifying a patient having breast cancer
AU2008202312A1 (en) Isolated ductal fluid sample
Pitman Hepatobiliary system and pancreas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040114

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040114

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080724

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081031